# Pathogenic Pathways and Therapeutic Strategies in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

**Authors:** Kenley M. Preval, Abigail O. Smith, Gregory J. Pazour

PMC · DOI: 10.33696/signaling.6.144 · 2026-01-28

## TL;DR

This paper explores the biological pathways involved in ADPKD and outlines potential new treatments to stop kidney cyst growth and disease progression.

## Contribution

The paper provides a comprehensive overview of pathogenic mechanisms and novel therapeutic strategies for ADPKD.

## Key findings

- Loss of polycystin function disrupts calcium and cAMP signaling, leading to cyst formation.
- Cyst growth involves Ca2+, cAMP, mTORC1, Src, and RTK pathways, along with chloride and water transporters.
- New therapies targeting these pathways may halt ADPKD progression.

## Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder and a major cause of end-stage renal disease. The disorder is primarily caused by pathogenic variants in PKD1 or PKD2, which encode the ciliary proteins polycystin-1 and polycystin-2. Loss of polycystin function disrupts calcium and cAMP signaling within the primary cilium, altering epithelial proliferation and fluid secretion that drive cyst formation and progressive kidney enlargement. Atypical forms of ADPKD arise from variants in genes required for the production of polycystins or for ciliary assembly. Cyst growth depends on proliferative and secretory pathways involving Ca2+, cAMP, mTORC1, Src, and receptor tyrosine kinases, while chloride and water transport via CFTR, ANO1, and NKCC1 drive luminal expansion. The vasopressin V2 receptor antagonists tolvaptan remains the only approved therapy, but new approaches are under investigation. These include inhibitors of mTORC1, Src, and RTKs, agents that block chloride secretion, small molecules and microRNAs that restore or enhance polycystin expression, and emerging cyst-directed cytotoxic therapies. By targeting aberrant epithelial responses to disrupted polycystin function, therapeutic intervention can be developed to halt cyst initiation, expansion, and progression to renal failure.

## Linked entities

- **Genes:** PKD1 (polycystin 1, transient receptor potential channel interacting) [NCBI Gene 5310], PKD2 (polycystin 2, transient receptor potential cation channel) [NCBI Gene 5311]
- **Proteins:** CFTR (CF transmembrane conductance regulator), ANO1 (anoctamin 1), SLC12A2 (solute carrier family 12 member 2), Crtc (CREB-regulated transcription coactivator), SRC (SRC proto-oncogene, non-receptor tyrosine kinase)
- **Chemicals:** tolvaptan (PubChem CID 216237)
- **Diseases:** Autosomal dominant polycystic kidney disease (MONDO:0004691), end-stage renal disease (MONDO:0004375)

## Full-text entities

- **Genes:** Ano1 (anoctamin 1, calcium activated chloride channel) [NCBI Gene 101772] {aka Tmem16a}, SLC12A2 (solute carrier family 12 member 2) [NCBI Gene 6558] {aka BSC, BSC-2, BSC2, CCC1, KILQS, NKCC1}, Kif2a (kinesin family member 2A) [NCBI Gene 16563] {aka C530030B14Rik, Kif2, Kns2, M-kinesin}, Avpr1a (arginine vasopressin receptor 1A) [NCBI Gene 54140] {aka AVPR, Avpr1, V1a, V1aR}, Mir17hg (Mir17 host gene (non-protein coding)) [NCBI Gene 75957] {aka 5033413D16Rik, Mirhg1, mir-17-92}, Pkhd1 (polycystic kidney and hepatic disease 1) [NCBI Gene 241035] {aka FPC, Tigm1}, Avpr2 (arginine vasopressin receptor 2) [NCBI Gene 12000] {aka ADHR, DI1, DIR, ND1, V2R, VPV2R}, Hsp84-3 (heat shock protein, 3) [NCBI Gene 104434] {aka 84kDa, Hsp90, hsp3}, IFT140 (intraflagellar transport 140) [NCBI Gene 9742] {aka CED5, MZSDS, PKD9, RP80, SRTD9, WDTC2}, Hnf1b (HNF1 homeobox B) [NCBI Gene 21410] {aka HNF-1-beta, HNF-1B, HNF-1Beta, Hnf1beta, LFB3, Tcf-2}, Pkd1l1 (polycystic kidney disease 1 like 1) [NCBI Gene 171395], Pkd2l1 (polycystic kidney disease 2-like 1) [NCBI Gene 329064] {aka B830002B15, PCL, PKD2L, Pkdl, TRPP3}, Bicc1 (BicC family RNA binding protein 1) [NCBI Gene 83675] {aka Bic-C, bpk, jcpk}, Tacstd2 (tumor-associated calcium signal transducer 2) [NCBI Gene 56753] {aka EGP-1, GA733-1, Ly97, TROP2}, PKD1 (polycystin 1, transient receptor potential channel interacting) [NCBI Gene 5310] {aka PBP, PC1, Pc-1, TRPP1, eliosin}, AVPR2 (arginine vasopressin receptor 2) [NCBI Gene 554] {aka ADHR, DI1, DIR, DIR3, NDI, NDI1}, Kif3a (kinesin family member 3A) [NCBI Gene 16568] {aka Kif3, Kifl, Kns3}, PKD2 (polycystin 2, transient receptor potential cation channel) [NCBI Gene 5311] {aka APKD2, PC2, PKD4, Pc-2, TRPP2}, Acta2 (actin alpha 2, smooth muscle, aorta) [NCBI Gene 11475] {aka 0610041G09Rik, Actvs, SMAalpha, SMalphaA, a-SMA, alphaSMA}, Pkd2 (polycystin 2, transient receptor potential cation channel) [NCBI Gene 18764] {aka C030034P18Rik, PC2, TRPP2}, Cftr (cystic fibrosis transmembrane conductance regulator) [NCBI Gene 12638] {aka Abcc7}, Avp (arginine vasopressin) [NCBI Gene 11998] {aka Vp, Vsp}, Pigr (polymeric immunoglobulin receptor) [NCBI Gene 18703], SRC (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 6714] {aka ASV, SRC1, THC6, c-SRC, p60-Src}, Tnk1 (tyrosine kinase, non-receptor, 1) [NCBI Gene 83813] {aka Kos1, Tnk1a, Tnk1b}, Pdgfrb (platelet derived growth factor receptor, beta polypeptide) [NCBI Gene 18596] {aka CD140b, PDGFR-1, Pdgfr}, CFTR (CF transmembrane conductance regulator) [NCBI Gene 1080] {aka ABC35, ABCC7, CF, CFTR/MRP, MRP7, TNR-CFTR}, ANO1 (anoctamin 1) [NCBI Gene 55107] {aka DOG1, INDMS, MYMY7, ORAOV2, TAOS2, TMEM16A}, Adcy5 (adenylate cyclase 5) [NCBI Gene 224129] {aka Ac5}, GANAB (glucosidase II alpha subunit) [NCBI Gene 23193] {aka G2AN, GIIA, GIIalpha, GLUII, PKD3}, Src (src proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 20779] {aka pp60c-src}, Mir17 (microRNA 17) [NCBI Gene 723905] {aka Mirn17, mir-17, mmu-mir-17}, SLC12A1 (solute carrier family 12 member 1) [NCBI Gene 6557] {aka BSC, BSC-1, BSC1, CCC2, NKCC2}, ALG8 (ALG8 alpha-1,3-glucosyltransferase) [NCBI Gene 79053] {aka CDG1H, PCLD3}, Adcy6 (adenylate cyclase 6) [NCBI Gene 11512] {aka AC6, mKIAA0422}, Tyro3 (TYRO3 protein tyrosine kinase 3) [NCBI Gene 22174] {aka Brt, Dtk, Etk-2, Rse, Sky, TK19-2}, ALG9 (ALG9 alpha-1,2-mannosyltransferase) [NCBI Gene 79796] {aka CDG1L, DIBD1, GIKANIS, LOH11CR1J}, Slc12a2 (solute carrier family 12, member 2) [NCBI Gene 20496] {aka 9330166H04Rik, BSC2, Nkcc1, mBSC2, mNKCC1, sy-ns}, Fgfr1 (fibroblast growth factor receptor 1) [NCBI Gene 14182] {aka Eask, FGFR-I, FLG, Fgfr-1, Flt-2, Fr1}, Met (met proto-oncogene, receptor tyrosine kinase) [NCBI Gene 17295] {aka HGF, HGFR, Par4, c-Met}, Mir21a (microRNA 21a) [NCBI Gene 387140] {aka Mir21, Mirn21, mmu-mir-21, mmu-mir-21a}, Pkd1 (polycystin 1, transient receptor potential channel interacting) [NCBI Gene 18763] {aka PC1, mFLJ00285}
- **Diseases:** cytotoxicity (MESH:D064420), skeletal dysplasia (MESH:C535858), Haploinsufficiency (MESH:C565160), Joubert syndrome (MESH:C536293), Nephronophthisis (MESH:C537699), PKD (MESH:C537180), hemorrhage (MESH:D006470), metabolic bone disease (MESH:D001851), hernias (MESH:D006547), liver and pancreatic cysts (MESH:D010181), IFT defects (MESH:C536778), cyst formation (MESH:D058426), cardiac valvular abnormalities (MESH:D006349), cystic disease (MESH:C563237), Cyst (MESH:D003560), cancer (MESH:D009369), urinary tract infections (MESH:D014552), fibrosis (MESH:D005355), anemia (MESH:D000740), renal failure (MESH:D051437), brain malformations (MESH:D020785), inherited renal disorder (MESH:C536482), kidney function decline (MESH:D007680), hypertension (MESH:D006973), pulmonary fibrosis (MESH:D011658), ADPKD (MESH:D016891), retinal degeneration (MESH:D012162), infection (MESH:D007239), breast and bladder cancer (MESH:D001943), Defects in kidney cilia (MESH:D007674), renal functional decline (MESH:D060825), cystic (MESH:D018297), inflammation (MESH:D007249), polyuria (MESH:D011141), ESRD (MESH:D007676), cystic kidney disease (MESH:D052177), reperfusion injury (MESH:D015427), hematuria (MESH:D006417), chronic kidney disease (MESH:D051436), Ischemia (MESH:D007511), intracranial aneurysms (MESH:D002532), injury (MESH:D014947), Senior-Loken syndrome (MESH:C537580), diabetes (MESH:D003920), cystic fibrosis (MESH:D003550), chronic myeloid leukemia (MESH:D015464), nephrolithiasis (MESH:D053040), THERAPY FOR POLYCYSTIC KIDNEY DISEASE (MESH:D007690), organ malformations (MESH:D000092124)
- **Chemicals:** benzbromarone (MESH:D001553), VX-809 (MESH:C569105), 11beta-dichloro and 11beta-dipropyl (-), Rapamycin (MESH:D020123), IMMU-132 (MESH:C000608132), IBMX (MESH:D015056), Tolvaptan (MESH:D000077602), Calcium (MESH:D002118), Tesevatinib (MESH:C571826), Bosutinib (MESH:C471992), niclosamide (MESH:D009534), Everolimus (MESH:D000068338), water (MESH:D014867), Nintedanib (MESH:C530716), STA-2842 (MESH:C000603842), C18 (MESH:C109760), chloride (MESH:D002712), forskolin (MESH:D005576), oligonucleotide (MESH:D009841), Bumetanide (MESH:D002034), urea (MESH:D014508), tamoxifen (MESH:D013629), VRT-325 (MESH:C507255), OPC31260 (MESH:C076251)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Mutations:** DeltaF508
- **Cell lines:** MDCK — Canis lupus familiaris (Dog), Spontaneously immortalized cell line (CVCL_0422)

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12842028/full.md

---
Source: https://tomesphere.com/paper/PMC12842028